Top Markets
Coin of the day
Solvonis Therapeutics plc Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS
Κατάταξη σε μετοχές #40468
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January... Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Τιμή μετοχής
$0.00204105
Κεφαλαιοποίηση
$138.92K
Αλλαγή (1 ημέρα)
5.63%
Αλλαγή (1 έτος)
-60.44%
Χώρα
GB
Εμπόριο Solvonis Therapeutics plc (SVNS)

Κατηγορία

Η τιμή SVNS με την κεφαλαιοποίηση του Β
Solvonis Therapeutics plc Solvonis Therapeutics plc
SVNS
$0.00204105
Κεφαλαιοποίηση αγοράς του Solvonis Therapeutics plc(SVNS)
Κεφαλαιοποίηση: $138.92K
Μέχρι το August 2026, η Solvonis Therapeutics plc έχει χρηματιστηριακή αξία $138.92K. Αυτό καθιστά τη Solvonis Therapeutics plc την 40468th πιο πολύτιμη εταιρεία στον κόσμο βάσει της κεφαλαιοποίησης σύμφωνα με τα δεδομένα μας. Η χρηματιστηριακή κεφαλαιοποίηση είναι η συνολική αγοραία αξία των μετοχών μιας εισηγμένης εταιρείας και χρησιμοποιείται συνήθως για να προσδιοριστεί η αξία μιας εταιρείας.
Ιστορικό κεφαλαιοποίησης αγοράς της Solvonis Therapeutics plc από 2022 έως 2026
SVNS σε σύγκριση με τα 5 πιο δημοφιλή stocks
Η τιμή για SVNS Το περιουσιακό στοιχείο B Η κεφαλαιοποίηση αγοράς του B Αποτελέσματα
Solvonis Therapeutics plc Solvonis Therapeutics plc
$80,358.71 $138.92K
$5.470T +3,937,121,289.65%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$65,630.42 $138.92K
$4.467T +3,215,518,705.67%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$61,330.28 $138.92K
$4.174T +3,004,836,235.16%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$54,361.71 $138.92K
$3.700T +2,663,415,733.27%
Solvonis Therapeutics plc Solvonis Therapeutics plc
$41,936.14 $138.92K
$2.854T +2,054,633,061.29%